Farxiga
E505482
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
SGLT2 inhibitor
ⓘ
antihyperglycemic agent ⓘ brand name drug ⓘ prescription medication ⓘ |
| approvalYear | 2014 ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | A10BK01 ⓘ |
| combinationTherapy |
may be used with insulin
ⓘ
may be used with metformin ⓘ may be used with other oral antidiabetic agents ⓘ |
| contraindication | patients with a history of serious hypersensitivity to dapagliflozin ⓘ |
| developer | AstraZeneca NERFINISHED ⓘ |
| doesNotTreat | type 1 diabetes mellitus ⓘ |
| dosageForm | tablet ⓘ |
| effect |
induces osmotic diuresis
ⓘ
lowers blood glucose levels ⓘ may reduce body weight ⓘ may reduce systolic blood pressure ⓘ |
| FDAApprovalStatus | approved ⓘ |
| hasActiveIngredient | dapagliflozin ⓘ |
| indication |
improve glycemic control in adults with type 2 diabetes
ⓘ
reduce risk of cardiovascular death and hospitalization for heart failure in adults with heart failure ⓘ reduce risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors ⓘ reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease ⓘ treatment of chronic kidney disease in adults ⓘ |
| lactationUse | caution advised ⓘ |
| marketingAuthorizationHolder | AstraZeneca NERFINISHED ⓘ |
| mechanismOfAction |
increases urinary glucose excretion
ⓘ
inhibits SGLT2 in the proximal renal tubules ⓘ reduces reabsorption of filtered glucose in the kidney ⓘ |
| monitoringParameter |
blood glucose
ⓘ
renal function ⓘ signs and symptoms of ketoacidosis ⓘ volume status ⓘ |
| pharmacologicClass | sodium-glucose cotransporter 2 inhibitor ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| risk |
acute kidney injury
ⓘ
genital mycotic infections ⓘ hypotension ⓘ ketoacidosis ⓘ urinary tract infections ⓘ volume depletion ⓘ |
| routeOfAdministration | oral ⓘ |
| takenWithOrWithoutFood | true ⓘ |
| treats | type 2 diabetes mellitus ⓘ |
| typicalDose |
10 mg once daily
ⓘ
5 mg once daily ⓘ |
| warning | not recommended in patients with severe renal impairment, end-stage renal disease, or on dialysis ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.